NO20010954L - Antioksidantsammensetning som innbefatter acetyl L-karnitin og <alfa>-lipoidsyre - Google Patents

Antioksidantsammensetning som innbefatter acetyl L-karnitin og <alfa>-lipoidsyre

Info

Publication number
NO20010954L
NO20010954L NO20010954A NO20010954A NO20010954L NO 20010954 L NO20010954 L NO 20010954L NO 20010954 A NO20010954 A NO 20010954A NO 20010954 A NO20010954 A NO 20010954A NO 20010954 L NO20010954 L NO 20010954L
Authority
NO
Norway
Prior art keywords
carnitine
lipoic acid
alfa
composition including
antioxidant composition
Prior art date
Application number
NO20010954A
Other languages
English (en)
Norwegian (no)
Other versions
NO20010954D0 (no
Inventor
Claudio Cavazza
Original Assignee
Sigma Tau Healthscience Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11406116&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20010954(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sigma Tau Healthscience Spa filed Critical Sigma Tau Healthscience Spa
Publication of NO20010954D0 publication Critical patent/NO20010954D0/no
Publication of NO20010954L publication Critical patent/NO20010954L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicinal Preparation (AREA)
NO20010954A 1998-09-01 2001-02-26 Antioksidantsammensetning som innbefatter acetyl L-karnitin og <alfa>-lipoidsyre NO20010954L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT1998RM000566A IT1302307B1 (it) 1998-09-01 1998-09-01 Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
PCT/IT1999/000268 WO2000011968A1 (en) 1998-09-01 1999-08-19 ANTIOXIDANT COMPOSITION COMPRISING ACETYL L-CARNITINE AND α-LIPOIC ACID

Publications (2)

Publication Number Publication Date
NO20010954D0 NO20010954D0 (no) 2001-02-26
NO20010954L true NO20010954L (no) 2001-04-25

Family

ID=11406116

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20010954A NO20010954L (no) 1998-09-01 2001-02-26 Antioksidantsammensetning som innbefatter acetyl L-karnitin og <alfa>-lipoidsyre

Country Status (28)

Country Link
US (1) US6365622B1 (is)
EP (1) EP1112005B2 (is)
JP (1) JP4361215B2 (is)
KR (1) KR20010079699A (is)
CN (1) CN1315835A (is)
AR (1) AR022076A1 (is)
AT (1) ATE228312T1 (is)
AU (1) AU773424B2 (is)
BR (1) BR9913288A (is)
CA (1) CA2341973C (is)
CZ (1) CZ2001541A3 (is)
DE (1) DE69904208T3 (is)
DK (1) DK1112005T4 (is)
EE (1) EE200100113A (is)
ES (1) ES2188214T5 (is)
HK (1) HK1039730A1 (is)
HU (1) HU229165B1 (is)
IL (1) IL141435A0 (is)
IS (1) IS5850A (is)
IT (1) IT1302307B1 (is)
MA (1) MA25284A1 (is)
NO (1) NO20010954L (is)
PL (1) PL212737B1 (is)
PT (1) PT1112005E (is)
SK (1) SK2632001A3 (is)
TN (1) TNSN99163A1 (is)
TR (1) TR200100610T2 (is)
WO (1) WO2000011968A1 (is)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6562869B1 (en) 1999-09-23 2003-05-13 Juvenon, Inc. Nutritional supplement for increased energy and stamina
WO2001021208A1 (en) 1999-09-23 2001-03-29 Juvenon Corporation Nutritional supplement for increased energy and stamina
CA2389623A1 (en) * 1999-11-03 2001-05-10 Juvenon, Inc. Method of treating benign forgetfulness
US6664287B2 (en) * 2000-03-15 2003-12-16 Bethesda Pharmaceuticals, Inc. Antioxidants
DE10036797A1 (de) * 2000-07-28 2002-02-07 Beiersdorf Ag Verwendung von Kombinationen mit einem Gehalt an Carnitinen
CN1477958A (zh) * 2000-10-31 2004-02-25 高露洁-棕榄公司 组合物及方法
JP2010142237A (ja) * 2000-10-31 2010-07-01 Colgate Palmolive Co 組成物及び方法
US20020076470A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
US8669282B2 (en) 2000-10-31 2014-03-11 Hill's Pet Nutrition, Inc. Companion animal compositions including lipoic acid and methods of use thereof
US6555573B2 (en) 2000-12-21 2003-04-29 The Quigley Corporation Method and composition for the topical treatment of diabetic neuropathy
PL363426A1 (en) * 2001-03-09 2004-11-15 Societe Des Produits Nestle S.A. Composition improving age-related physiological deficits and increasing longevity
SE0102380D0 (sv) * 2001-07-02 2001-07-02 Macronova Ab Kräm för behandling av åldersförändringar i huden hos människa
US6923960B2 (en) 2001-10-03 2005-08-02 Vsl Pharmaceuticals Inc. Antioxidant combination composition and use thereof
NZ533439A (en) * 2001-12-19 2006-06-30 The Quigley Corp Methods for the treatment of peripheral neural and vascular ailments using flavonoid compositions
US20060127505A1 (en) * 2002-01-16 2006-06-15 David Haines Anti-inflammatory formulations
EP1476440A4 (en) * 2002-02-22 2005-06-01 Albany College Of Pharmacy METHODS AND COMPOUNDS USEFUL IN INHIBITION BY RADICAL AND / OR OXIDIZING AGGRESSION AND IN THE TREATMENT AND PREVENTION OF DISEASE
JP2006506361A (ja) * 2002-10-11 2006-02-23 クレアグリ， インコーポレイテッド カルニチンおよび酸化防止ポリフェノールの治療用組合せ
US7083813B2 (en) 2002-11-06 2006-08-01 The Quigley Corporation Methods for the treatment of peripheral neural and vascular ailments
DE10258239A1 (de) * 2002-12-13 2004-06-24 Degussa Ag Formulierung enthaltend alpha-Liponsäure(-Derivate) als alleinigen Wirkstoff bei nichtchronischen alkoholinduzierten Intoxikationen
ITRM20020620A1 (it) * 2002-12-13 2004-06-14 Sigma Tau Ind Farmaceuti Uso delle carnitine per la prevenzione e/o il trattamento dei disturbi causati dall'andropausa.
US20040265345A1 (en) * 2003-06-30 2004-12-30 Perricone Nicholas V. Treatment of skin damage using acetyl carnitine and lipoic acid
US20050214413A1 (en) * 2003-08-26 2005-09-29 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
US7999003B2 (en) * 2003-08-26 2011-08-16 Mannatech, Incorporated Antioxidant compositions and methods thereto
EP1706146B1 (en) * 2003-12-31 2013-08-21 K-Pax Pharmaceuticals, Inc. Nutrient compositions and use thereof for enhanced effectiveness of the immune system
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US8569367B2 (en) * 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
JP5138380B2 (ja) * 2004-11-24 2013-02-06 ヒルズ・ペット・ニュートリシャン・インコーポレーテッド 動物における免疫応答を増大させる方法
WO2006058278A2 (en) * 2004-11-24 2006-06-01 Hill's Pet Nutrition, Inc. Methods for improving liver clearance of xenobiotic substances in an animal
US20090176864A1 (en) * 2004-11-24 2009-07-09 Hill's Pet Nutrition, Inc. Methods For Improving Hepatic and Immune Function In An Animal
DK1830883T3 (da) 2004-12-29 2013-11-25 Hills Pet Nutrition Inc Fremgangsmåde til at hæmme en nedgang i indlæring og/eller hukommelse hos dyr
US8148325B2 (en) * 2004-12-30 2012-04-03 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
US8252742B2 (en) * 2004-12-30 2012-08-28 Hill's Pet Nutrition, Inc. Methods for enhancing the quality of life of a senior animal
JP5685362B2 (ja) * 2005-04-26 2015-03-18 シグマ−タウ・インドゥストリエ・ファルマチェウチケ・リウニテ・ソシエタ・ペル・アチオニＳｉｇｍａ−Ｔａｕ Ｉｎｄｕｓｔｒｉｅ Ｆａｒｍａｃｅｕｔｉｃｈｅ Ｒｉｕｎｉｔｅ Ｓｏｃｉｅｔａ Ｐｅｒ Ａｚｉｏｎｉ 有痛性末梢糖尿病性神経障害の予防のためのアセチルｌ−カルニチン
EP1906912B1 (en) 2005-07-14 2012-08-15 Hill's Pet Nutrition, Inc. Method for prolonging the life of animals
US8318954B2 (en) * 2006-02-23 2012-11-27 Nou Life Sciences, Inc. Cleavable carnitine compound
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
CN101057857B (zh) * 2006-04-21 2011-05-18 中国科学院上海生命科学研究院 一种预防与改善帕金森氏症的组合物及其制法
KR100811110B1 (ko) * 2007-02-21 2008-03-06 주식회사 디피아이 솔루션스 수분산성 α-리포산 캡슐 조성물을 함유하는 어류의 면역력증강용 사료첨가제 및 그 사용방법.
US20080226696A1 (en) * 2007-03-15 2008-09-18 Ben Treadwell Methods of improving learning abilities of aged companion animals
US20100255109A1 (en) * 2007-08-06 2010-10-07 Biogenics, Inc. Stabilized antioxidant particles, composition comprising the same and method for preparing the same
KR20090014568A (ko) * 2007-08-06 2009-02-11 (주)바이오제닉스 코팅된 알파리포산 입자, 이를 포함하는 조성물 및 그 제조방법
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
US7943163B2 (en) * 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
KR100903549B1 (ko) * 2008-07-29 2009-06-23 주식회사 카이로제닉스 균질한 결정성의 아세틸-ｌ-카르니틴과 티옥트산 칼륨염의 복합염, 이의 제조방법 및 이를 포함하는 약학적 조성물
US20110217252A1 (en) * 2008-11-11 2011-09-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
EP2389931A1 (en) * 2010-05-21 2011-11-30 Raw Materials Internatinal LLC Pharmaceutical aqueous compositions comprising lipoic acid as an antioxidant
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
US8957048B2 (en) 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
CA2858574C (en) 2011-12-07 2017-05-30 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
US20140371280A1 (en) * 2013-03-15 2014-12-18 Shinichi Okuyama Method of treating diabetic peripheral neuropathy through amendment of pre-neuronal diabetic coagulative micro-angiopathy and neuronal deficiency of mitochondrial ATP production, and through induction of neuronal regeneration
US20190290609A1 (en) * 2014-03-19 2019-09-26 Epitech Group S.P.A. Pharmaceutical composition comprising palmitoylethanolamide and l-acetylcarnitine
WO2016065360A1 (en) * 2014-10-24 2016-04-28 Robert Shorr Methods and compositions for the treatment of pre-diabetes, diabetes and metabolic syndrome
NZ732058A (en) 2014-11-25 2023-06-30 Allergan Inc Stabilized omega-3 ophthalmic compositions
DK3277273T3 (da) * 2015-03-31 2020-04-14 Kolinpharma S P A Sammensætning til behandling af neuropatier og/eller neuropatisk smerte
US11639494B2 (en) 2015-08-24 2023-05-02 Vitrolife Sweden Ab Culture medium
US11998554B2 (en) * 2018-09-10 2024-06-04 URIACH ITALY S.r.l. Composition comprising lipoic acid and vitamin D for the prevention and the treatment of neurodegenerative diseases and peripheral neuropathies
CN111467385B (zh) * 2019-01-24 2022-05-17 深圳市华大农业应用研究院 组合物在预防或治疗神经退行性疾病中的用途
US12521407B2 (en) 2019-04-18 2026-01-13 Simo Rasi Composition for use in prevention or reduction of oxidative stress and neurodegenerative diseases
US12208077B2 (en) 2021-04-06 2025-01-28 Celagenex Research (India) Pvt. Ltd. Synergistic composition for potentiating stabilized ATP
CN112999220B (zh) * 2021-04-07 2022-12-13 中国人民解放军南部战区总医院 α-硫辛酸在作为和/或制备金属β-内酰胺酶抑制剂中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5668117A (en) * 1991-02-22 1997-09-16 Shapiro; Howard K. Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
WO1997002041A1 (en) * 1995-07-03 1997-01-23 Crandall Wilson T Transdermal and oral treatment of androgenic alopecia
IT1283967B1 (it) * 1996-03-29 1998-05-07 Sigma Tau Ind Farmaceuti Uso di l-carnitina o derivati della l-carnitina ed antiossidanti nella prevenzione e trattamento di patologie derivanti da danni ossidativi
US5977162A (en) * 1996-09-16 1999-11-02 Seidman; Michael D. Therapeutic treatment for auditory function
JP2001511153A (ja) * 1997-02-04 2001-08-07 ブイ． コスバブ，ジョン 血管変性性疾患の予防および処置のための組成物および方法
IT1291113B1 (it) 1997-03-20 1998-12-29 Sigma Tau Ind Farmaceuti Composizione nutritiva terapeutica per soggetti affetti da diabete mellito
US5916912A (en) 1997-06-16 1999-06-29 The Regents Of The University Of California Dietary composition for enhancing metabolism and alleviating oxidative stress

Also Published As

Publication number Publication date
EP1112005B2 (en) 2010-03-24
BR9913288A (pt) 2001-05-22
CA2341973C (en) 2009-05-12
DE69904208T3 (de) 2010-09-30
DE69904208D1 (de) 2003-01-09
DK1112005T3 (da) 2002-12-30
TNSN99163A1 (fr) 2005-11-10
PT1112005E (pt) 2003-03-31
AU773424B2 (en) 2004-05-27
US6365622B1 (en) 2002-04-02
KR20010079699A (ko) 2001-08-22
EE200100113A (et) 2002-06-17
IS5850A (is) 2001-02-16
CA2341973A1 (en) 2000-03-09
CN1315835A (zh) 2001-10-03
JP4361215B2 (ja) 2009-11-11
AR022076A1 (es) 2002-09-04
ES2188214T5 (es) 2010-06-08
IL141435A0 (en) 2002-03-10
ITRM980566A1 (it) 2000-03-01
IT1302307B1 (it) 2000-09-05
ES2188214T3 (es) 2003-06-16
DK1112005T4 (da) 2010-06-14
NO20010954D0 (no) 2001-02-26
MA25284A1 (fr) 2001-12-31
JP2002523435A (ja) 2002-07-30
AU5387199A (en) 2000-03-21
HUP0102909A3 (en) 2002-12-28
TR200100610T2 (tr) 2001-07-23
DE69904208T2 (de) 2003-08-28
PL346318A1 (en) 2002-01-28
SK2632001A3 (en) 2001-08-06
HK1039730A1 (zh) 2002-05-10
CZ2001541A3 (cs) 2001-09-12
ATE228312T1 (de) 2002-12-15
HUP0102909A2 (hu) 2002-03-28
PL212737B1 (pl) 2012-11-30
ITRM980566A0 (it) 1998-09-01
WO2000011968A1 (en) 2000-03-09
EP1112005B1 (en) 2002-11-27
WO2000011968A8 (en) 2000-05-11
EP1112005A1 (en) 2001-07-04
HU229165B1 (en) 2013-09-30

Similar Documents

Publication Publication Date Title
NO20010954L (no) Antioksidantsammensetning som innbefatter acetyl L-karnitin og &lt;alfa&gt;-lipoidsyre
DE60024593D1 (de) Kosmetische, diätetische oder pharmazeutische zusammensetzung die thioctsäure und cystein enthalten
NO20006431L (no) Sammensetning for å forhindre og/eller behandle osteoporose og forandringer på grunn av menopausalsyndrom
NO20006430L (no) Neurobeskyttende sammensetning for forhindring og/eller behandling av nerve- og atferdsforandringer på grunn av angsttilstander eller depresjoner
BR9814484A (pt) &#34;pró-drogas de inibidores de aspartil protease&#34;
DK0787489T3 (da) Sammensætning, der indeholder propionyl-L-carnitin og hydroxycitronsyre eller pantothensyre
PL369108A1 (en) 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
BR0206381A (pt) Derivados do ácido fumárico como inibidor de nf-kappab
NO20042596L (no) Inbibitorer av 11-beta-hydroksy steroid dehydrogenase type 1
KR940006578A (ko) 2-(3,4-디메톡신나모일) 아미노벤조산
TR200102811T2 (tr) Oral uygulama için, tolpersiyon içeren farmasötik preparat.
TR200100333T2 (tr) Bir karnitin ve bir karotenoit içeren antioksidan, antiproliferos bileşim
NO20021640L (no) Sammensetning til forebygging og/eller behandling av kretslöpsykdommer som omfatter derivater av L-karnitin ogekstrakter av Gingo biloba
MXPA04003611A (es) Piperidina- y piperazinacetaminas como inhibidores de la 17 beta-hidroxiesteroide deshidrogenasa tipo 3 para el tratamiento de enfermedades androgeno-dependientes.
TR200003737T1 (tr) Diyet takviyesi ya da ilaç olarak kullanılan bileşim
HUP0303628A2 (hu) Ketosavakból és aminosavakból képzett gyomornedválló sók, valamint azok alkalmazása gyógyszerkészítmények előállítására
DK1409449T3 (da) Alpha-ketoglutarater af aktive ingredienser og sammensætninger omfattende disse
TR200101344T2 (tr) Propionil L-karnitinden ve bir flavonoid&#39;den oluşan antioksidan bileşim
NO20020917D0 (no) Behandling av migrene ved administrering av en &lt;alfa&gt;- liponsyre eller derivater derav
IT1307278B1 (it) Composizione per la prevenzione e/o il trattamento di disturbi dovutiad un alterato metabolismo dei lipidi, che comprende propionil
WO2001007039A3 (en) L-acetylcarnitine and l-propionylcarnitine containing composition for the prevention and treatment of kidney dysfunctions and diseases
NO20023117L (no) Sammensetning for forebygging og/eller behandling av lipidmetabolismeforstyrrelser og allergiske former
ATE259778T1 (de) Nicht-hygroskopische salze aktiver inhaltsstoffe, die therapeutische und/oder ernährungsphysiologische eigenschaften haben und oral verabreichbare zusammensetzungen, die diese enthalten
PT1178960E (pt) Analogos da vitamina d e sua utilizacao farmaceutica
TR200200015T2 (tr) L-Karnitin ve türevleri ile crataegus ekstreleri içeren kardiyoaktif bileşim

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application